Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29316577 | 0.89 | CYP1A2 (0.46) | CYP1A2MAPTSMN1; SMN2GAACYP2C19 | |
| SCHEMBL29316553 | 0.80 | MAPT (0.49) | CYP1A2MAPTSMN1; SMN2GAACYP2C19 | |
| SCHEMBL801053 | 0.79 | CYP1A2 (0.58) | CYP1A2MAPTSMN1; SMN2GAACYP2C19 | |
| SCHEMBL2454872 | 0.78 | MAPT (0.47) | CYP1A2MAPTSMN1; SMN2GAACYP2C19 | |
| SCHEMBL10045803 | 0.78 | CES1 (0.44) | CYP1A2MAPTSMN1; SMN2GAACYP2C19 | |
| SCHEMBL10074433 | 0.76 | CYP1A2 (0.39) | CYP1A2MAPTSMN1; SMN2GAACYP2C19 | |
| SCHEMBL69653 | 0.76 | MAPT (0.64) | CYP1A2MAPTSMN1; SMN2GAACYP2C19 | |
| SCHEMBL3885590 | 0.76 | CYP1A2 (0.68) | CYP1A2MAPTSMN1; SMN2CYP2C19TP53 | |
| SCHEMBL13893212 | 0.76 | CYP1A2 (0.53) | CYP1A2MAPTSMN1; SMN2GAACYP2C19 | |
| SCHEMBL24418750 | 0.74 | SUCNR1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518928-B2 | Therapeutic compounds | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120071527-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-03-22 | — | — | US | disclosed |
| WO-2007127173-A2 | THERAPEUTIC COMPOUNDS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071527-A1 | THERAPEUTIC COMPOUNDS | TOP2B, DDB1, TOP1 | CYP1A2 4160/4885MAPT 2056/4885SMN1; SMN2 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.